Recent events, particularly the reversal of the long-standing Roe v. Wade decision that guaranteed women’s right to have an abortion, have put women’s health matters squarely in the spotlight. It also opens up an opportunity for biomed firms involved in the fields of reproductive health and contraception. So today we’ll look at two stocks closely tied to the contraceptive business – to the research and marketing of new methods. But that's not all, according to TipRanks database, these are stocks that are getting the thumbs up from the Wall Street analysts in the form of Buy ratings. Let’s dive in and see what the analysts have to say about them. Femasys (FEMY) We’ll start with Femasys, a medical research company focused on the two extremes of reproductive health: infertility treatments and permanent contraception. The second track, permanent contraception, offers a larger potential market; according to population research, some 13 million women in the US choose not to have children, opening up a large potential patient base for an effective, permanent contraceptive method. Femasys starts by noting that the most commonly used permanent method, tubal ligation, requires a surgical procedure. The company’s FemBloc method is designed for application as an outpatient procedure in the doctor’s office, making it easier on the patient. The procedure delivers a biopolymer to the opening of the patient’s Fallopian tubes, encouraging scar tissue growth that will permanently block both the fertilization of egg cells and the movement of egg cells to the womb. The procedure is followed up through ultrasound imaging about 3 months after application to judge the success of the blockage. The FemBloc system and procedure are currently undergoing clinical trials, and Femasys has initiated a phase 2 study. This trial is expected to complete enrollment in 3Q22. Earlier trials of FemBloc showed that it was well-tolerated by patients, and considered easier and less painful than surgical options. Femasys is on track to file an investigational device exemption (IDE) to allow a pivotal trial later this year; that will precede a premarket approval (PMA) filing with the FDA, tentatively set for 1Q23. These facts lie behind Maxim analyst 's optimistic view of the company. He writes, "FemBloc represents the only non-surgical permanent birth control solution in development, with significant advantages over the only existing option, tubal ligation surgery... Unlike with Essure, FemBloc does not involve a permanent implant, and thus can limit long-term adverse events and provide improved safety profile. The procedure also limits risks associated with the tubal ligation procedure, as it does not involve surgery..." To this end, McCarthy rates FEMY a Buy, while his $5 target price suggests a one-year upside potential of ~96%. (To watch McCarthy’s track record, ) Overall, it’s clear that Wall Street is sanguine about this small biomed research company; Femasys has 3 recent analyst reviews on file and all are to Buy, making the consensus rating a Strong Buy. The shares are priced at just $2.57 and their $9.33 average target indicates potential for a robust 263% gain in the next 12 months. () All of this has attracted attention from Laidlaw analyst , who believes Phexxi's sales are likely to take off in 2022 and beyond. Unsurprisingly, Jen gives EVFM shares a Buy rating, with a $3.50 price target that implies a one-year upside potential of 227%. (To watch Jen’s track record, ) The projection amongst Jen's colleagues is for plenty of upside, too. Shares are currently priced at $1.07 and their $2.63 average target suggests growth of ~146% this year. Overall, the stock has a Moderate Buy consensus rating, based on 3 Buys and 1 Sell. () To find good ideas for medical stocks trading at attractive valuations, visit TipRanks’ , a newly launched tool that unites all of TipRanks’ equity insights. More